FDA grants expanded use of ChromaCode's COVID-19 test

2020 01 21 22 13 2411 Virus Coronavirus 400

The U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) of ChromaCode's High-Definition Polymerase Chain Reaction (HDPCR) SARS-CoV-2 Assay to include several new real-time PCR instruments and the use of 384-well plates.

The expanded authorization has the potential to more than quadruple throughput for laboratories, according to the company.

"The EUA authorization for use with even more instrument platforms and 384-well plates will enable labs using ChromaCode's assay to continue to rapidly scale and meet the demand for high-volume testing while delivering excellent accuracy and variant inclusivity," said ChromaCode Co-Founder and CEO Alex Dickinson, in a news release.

ChromaCode's HDPCR SARS-CoV-2 Assay is now compatible with industry leading extraction and amplification systems, Dickinson added.

Page 1 of 35
Next Page